Pignata, S., Cecere, S. C. and Di Maio, M. (2016) “Bevacizumab as first-line treatment of ovarian cancer: strengths and weaknesses of subgroup analyses:  ”, Cancer Breaking News, 4(1), pp. 45–47. doi: 10.19156/cbn.2016.0009.